youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
VRTX:NASDAQ
Vertex Pharmaceuticals Inc
$558.88
arrow_upward
+3.50%(+18.88) 1D
$554.00
arrow_downward
-0.87% (-4.88)bedtimeAfter hours
Closed: Oct 30, 3:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VRTX...
Open
$550.73
High
$563.80
Low
$549.89
Mkt. cap
141.65B
Avg. vol.
1.24M
Volume
3.03M
P/E ratio
32.52
52-wk high
$563.80
52-wk low
$403.16
EPS
$17.19
Beta
0.28
Shares outstanding
253.46M
No. of employees
6K
Open
$550.73
High
$563.80
Low
$549.89
Mkt. cap
141.65B
Avg. vol.
1.24M
Volume
3.03M
P/E ratio
32.52
52-wk high
$563.80
52-wk low
$403.16
EPS
$17.19
Beta
0.28
Shares outstanding
253.46M
No. of employees
6K
News stories
From web sources and news partners
Yahoo Finance
·
9 hours ago
Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?
Profile
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England. Wikipedia
About Vertex Pharmaceuticals Inc
CEOReshma Kewalramani
Employees6.4K
Founded1989
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitevrtx.com
Analyst ratings
Based on 25 analysts giving stock ratings to VRTX in the past 3 months
Strong buy
Buy
22
Hold
3
Sell
0
12-month forecast
Based on 25 Wall Street analysts offering 12 month price targets for VRTX in the last 3 months.
Highest
Current $558.88
$667.00 (+19.35%)
Average
$589.50 (+5.48%)
Lowest
$442.00 (-20.91%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Risinger Leerink Partners | Buy | Reiterated | - | - | 10/27/2026 |
Geoff Meacham Citi | Buy | Maintained | $585.00 | +4.7% | 10/27/2026 |
Louise Chen Scotiabank | Buy | Maintained | $558.00 | -0.2% | 10/26/2026 |
Carter Gould Cantor Fitzgerald | Buy | Reiterated | $595.00 | +6.5% | 10/25/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $654.00 | +17% | 10/25/2026 |
Phil Nadeau TD Cowen | Buy | Reiterated | $550.00 | -1.6% | 10/26/2026 |
Andrew Fein H.C. Wainwright | Buy | Maintained | $641.00 | +14.7% | 10/26/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Maintained | $667.00 | +19.3% | 10/26/2026 |
Michael Yee UBS | Buy | Reiterated | $615.00 | +10% | 10/26/2026 |
Mohit Bansal Wells Fargo | Buy | Maintained | $550.00 | -1.6% | 10/15/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $600.00 | +7.4% | 10/12/2026 |
Brian Abrahams RBC Capital | Buy | Maintained | $576.00 | +3.1% | 10/08/2026 |
Terence Flynn Morgan Stanley | Buy | Reiterated | $665.00 | +19% | 10/07/2026 |
Jeffrey Walch Bernstein | Buy | Maintained | $608.00 | +8.8% | 09/25/2026 |
Akash Tewari Jefferies | Buy | Maintained | $640.00 | +14.5% | 09/23/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $640.00 | +14.5% | 09/23/2026 |
Danielle Brill Truist Financial | Buy | Maintained | - | - | 09/23/2026 |
Whitney Ijem Canaccord Genuity | Hold | Maintained | $442.00 | -20.9% | 09/23/2026 |
Paul Matteis Stifel Nicolaus | Hold | Maintained | - | - | 09/22/2026 |
Eliana Merle Barclays | Buy | Maintained | $617.00 | +10.4% | 09/23/2026 |
Myles Minter William Blair | Buy | Maintained | - | - | 09/22/2026 |
Jessica Fye J.P. Morgan | Buy | Initiated | $560.00 | +0.2% | 09/11/2026 |
William Pickering Bernstein | Buy | Maintained | $608.00 | +8.8% | 08/11/2026 |
Naz Rahman Maxim Group | Buy | Reiterated | $575.00 | +2.9% | 08/05/2026 |
Andy Chen Wolfe Research | Buy | Maintained | $557.00 | -0.3% | 08/03/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $535.00 | -4.3% | 08/04/2026 |
Joseph Stringer Needham | Hold | Maintained | - | - | 08/04/2026 |
Sadia Rahman Wells Fargo | Buy | Reiterated | $550.00 | -1.6% | 07/13/2026 |
Brian Skorney Robert W. Baird | Sell | Maintained | $350.00 | -37.4% | 07/07/2026 |
Unknown Analyst Raymond James | Hold | Maintained | - | - | 06/24/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $546.00 | -2.3% | 06/02/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $515.00 | -7.9% | 05/20/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $600.00 | +7.4% | 05/05/2026 |
Hans Engel Erste Group | Hold | Maintained | - | - | 05/05/2026 |
Joon Lee Truist Financial | Buy | Maintained | $525.00 | -6.1% | 03/11/2026 |
Next call in 37:17:45
Mon, Nov 2, 11:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $4.75
Revenue / Est. (USD)
- / 3.43B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 3.08B | 3.19B | 2.99B | 3.33B |
Cost of goods sold | 1.39B | 1.44B | 1.35B | 1.48B |
Cost of revenue | 1.39B | 1.44B | 1.35B | 1.48B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 445.10M | 487.00M | 493.70M | 582.20M |
Operating expense | 445.10M | 487.00M | 493.70M | 582.20M |
Total operating expenses | 1.84B | 1.93B | 1.85B | 2.07B |
Operating income | 1.24B | 1.26B | 1.14B | 1.27B |
Other non operating income | 14.60M | -14.30M | -6.70M | 46.20M |
EBT including unusual items | 1.30B | 1.33B | 1.25B | 1.39B |
EBT excluding unusual items | 1.35B | 1.38B | 1.25B | 1.42B |
Income tax expense | 215.90M | 139.90M | 221.50M | 292.00M |
Effective tax rate | 16.62% | 10.51% | 17.68% | 20.98% |
Other operating expenses | - | - | - | - |
Net income | 1.08B | 1.19B | 1.03B | 1.10B |
Net profit margin | 35.20% | 37.34% | 34.53% | 32.99% |
Earnings per share | 4.80 | 5.03 | 4.47 | 4.73 |
Interest and investment income | 125.70M | 121.90M | 114.80M | 120.60M |
Interest expense | -3.30M | -3.30M | - | - |
Net interest expenses | 122.40M | 118.60M | 114.80M | 120.60M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.29B | 1.29B | 1.19B | 1.33B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events